<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117489</url>
  </required_header>
  <id_info>
    <org_study_id>CORT118335-861</org_study_id>
    <nct_id>NCT05117489</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients&#xD;
      with presumed Nonalcoholic Steatohepatitis (NASH)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 1b, Open-Label Study will assess the safety, efficacy and pharmacokinetics (PK) of&#xD;
      miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH).&#xD;
&#xD;
      Patients who meet the criteria for the study CORT-118335-861 will be enrolled on Day 1 into 1&#xD;
      of 4 cohorts and receive miricorilant, escalated every 4 weeks, from 150mg once daily, to&#xD;
      600mg once daily, in 150mg increments over 16 weeks or a steady dose of either 150mg, 300mg&#xD;
      or 450mg miricorilant once daily, for up to 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change from Baseline in liver-fat content assessed by MRI-PDFF compared to Baseline.</measure>
    <time_frame>Baseline Day 1 up to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in aspartate aminotransferase (AST).</measure>
    <time_frame>Baseline Day 1 up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in alanine aminotransferase (ALT).</measure>
    <time_frame>Baseline Day 1 up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in gamma-glutamyl transferase (GGT).</measure>
    <time_frame>Baseline Day 1 up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in enhanced liver fibrosis score (ELF).</measure>
    <time_frame>Baseline Day 1 up to Week 16</time_frame>
    <description>ELF numerical values are calculated from serum measurements of hyaluronic acid (HA), tissue inhibitor of metalloproteinases-1 (TIMP-1), and type III procollagen (PIIINP) using the formula: ELF score = 2.494 + 0.846 In [HA] + 0.735 In [PIIINP] + 0.391 In [TIMP-1], and range on a continuous scale. Liver fibrosis is unlikely with scores &lt;6.7 and increasingly likely with higher scores.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Dose escalation of miricorilant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant escalated every 4 weeks from 150 mg once daily, to 600 mg once daily in 150mg increments over 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - 150 mg of miricorilant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - 300 mg of miricorilant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 300 mg once daily, for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - 450 mg of miricorilant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 450 mg once daily, for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miricorilant Dose Escalation</intervention_name>
    <description>Miricorilant 150 mg dose escalating up to 600 mg every 4 week in 150mg increments for oral dosing</description>
    <arm_group_label>Cohort 1 - Dose escalation of miricorilant</arm_group_label>
    <other_name>CORT118335</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miricorilant 150 mg</intervention_name>
    <description>Miricorilant 150 mg for oral dosing</description>
    <arm_group_label>Cohort 2 - 150 mg of miricorilant</arm_group_label>
    <other_name>CORT118335</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miricorilant 300 mg</intervention_name>
    <description>Miricorilant 300 mg for oral dosing</description>
    <arm_group_label>Cohort 3 - 300 mg of miricorilant</arm_group_label>
    <other_name>CORT118335</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miricorilant 450 mg</intervention_name>
    <description>Miricorilant 450 mg for oral dosing</description>
    <arm_group_label>Cohort 4 - 450 mg of miricorilant</arm_group_label>
    <other_name>CORT118335</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Have a diagnosis of NASH based on a biopsy obtained within the last year OR Have a&#xD;
        diagnosis of presumed NASH based on blood tests and scans&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated in another clinical trial within the last year and received active&#xD;
             treatment for NASH&#xD;
&#xD;
          -  Have participated in another clinical trial for any other indication within the last 3&#xD;
             months&#xD;
&#xD;
          -  Are pregnant or lactating women&#xD;
&#xD;
          -  Have a BMI &lt;18 kg/m2&#xD;
&#xD;
          -  Have had liver transplantation or plan to have liver transplantation during the study&#xD;
&#xD;
          -  Have type 1 diabetes or poorly controlled type 2 diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Butler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Lead</last_name>
    <phone>650-327-3270</phone>
    <email>Study861ctgov@corcept.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 207</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 209</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 210</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 211</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 213</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 212</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

